Changes in fecal flora and comparative multiple-dose pharmacokinetics of ceftibuten, cefpodoxime proxetil and amoxycillin/clavulanate

Clinical Microbiology and Infection

Volumn 5, Issue 6, 1999, Pages 339-354

  Hamacher, Jürg ^a   Luepke, Jörg ^a   Reidenberg, Bruce E ^b   Nord, Carl Erik ^c   Borner, Klaus ^e   Koeppe, Peter ^e   Bristol, David ^b   Lode, Hartmut ^a,d  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b MERCK RESEARCH LABORATORIES   (United States)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d Hospital Zehlendorf   (Germany)

^e NONE

Author keywords

Amoxycillin clavulanate; Cefpodoxime proxetil; Ceftibuten; Fecal flora; Pharmacokinetics; Statistical analysis; Triple crossover design; lactamase activity

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAMASE; CEFPODOXIME PROXETIL; CEFTIBUTEN; CEPHALOSPORIN DERIVATIVE;

ADULT; ARTICLE; BIOASSAY; CLINICAL TRIAL; CROSSOVER PROCEDURE; DIARRHEA; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG URINE LEVEL; ENZYME ACTIVITY; FECES MICROFLORA; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; ISOMER; MALE; MYCOSIS; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PRURITUS; STATISTICAL ANALYSIS; TIME; VAGINITIS;

EID: 0032993364     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.1999.tb00153.x     Document Type: Article

References (69)

1. Moellering Jr RC, Sentochnik DE. Cephalosporins. In Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious diseases, 1st edn. Philadelphia, London, Toronto: WB Saunders Company, Harcourt Brace Jovanovich, Inc., 1992: 172-82.
2. Fassbender M, Lode H, Schaberg T, Borner K, Koeppe P. Pharmacokinetics of new oral cephalosporins, including a new carbacepheme. Clin Infect Dis 1993; 16: 646-53.
3. Jones RN. Ceftibuten: a review of antimicrobial activity, spectrum and other microbiologic features. Pediatr Infect Dis J 1993; 12: S37-44.
4. Wiseman LR, Balfour JA. Ceftibuten. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1994; 47: 784-808.
5. Lode H, Fassbender M, Schaberg T, Borner K, Koeppe P. Comparative pharmacokinetics of the new oral cephalosporins. Drugs 1994; 47(suppl 3): 10-20.
6. Neu H. Ceftibuten: minimal inhibitory concentrations, post-antibiotic effect, beta-lactamase stability - a rationale for dosing programs. Pediatr Infect Dis J 1993; 12: S49-54.
7. Jones RN, Barry AL. In vitro evaluation of ceftibuten (7432-S; SCH 39720), a novel orally administered cephalosporin. Chemioterapia 1988; 7: 283-6.
8. Kammer RB, Ress R. Randomized comparative study of ceftibuten versus cefaclor in the treatment of acute lower respiratory infections. Diagn Microbiol Infect Dis 1991; 14: 101-5.
9. Verhaegen J, Verbist L. In-vitro activity of 21 beta-lactam antibiotics against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 1998; 41: 381-5.
10. Barr WH, Affrime M, Lin CC, Batra V. Pharmacokinetics of ceftibuten in children. Pediatr Infect Dis J 1993; 12(suppl): S55-63.
11. Brismar B, Edlund C, Nord CE. Effect of ceftibuten on the normal intestinal microflora. Infection 1993; 21: 25-7.
12. Todd WM. Cefpodoxime proxetil: a comprehensive review. Int Antimicrob Agents 1994; 4: 37-62.
13. Frampton JE, Brogden RN, Langtry HD, Buckley MN. Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992; 44: 889-917.
14. Cox CE, Graveline JF, Luongo JM. Review of clinical experience in the United States with Cefpodoxime proxetil in adults, with uncomplicated urinary tract infections. Drugs 1991; 42(suppl 1): 41-50.
15. Safran C. Cefpodoxime proxetil: dosage, efficacy and tolerance in adults suffering from respiratory tract infections. J Antimicrob Chemother 1990; 26(suppl E): 93-101.
16. Tack KJ, Wilks NE, Semerdjian G, et al. Cefpodoxime proxetil in the treatment of skin and soft tissue infections. Drugs 1991; 42(suppl 3): 51-6.
17. Stein GE, Christensen S, Mummaw N. Treatment of uncomplicated urinary tract infection with ceftibuten. Infection 1991; 19: 124-6.
18. McCabe R, Rumans L, Perrotta R, Mogabgab W. Comparison of the efficacy and safety of ceftibuten and cefaclor in the treatment of pneumonia and bronchiectasis. J Chemother 1993; 5: 124-32.
19. Kammer RB. Worldwide safety experience with ceftibuten pediatric suspensions. Pediatr Infect Dis J 1993; 12: S92-4.
20. McLinn SE, Mccarty JM, Perrotta R, Pichiero ME, Reidenberg BE, Members of the Ceftibuten Otitis Media United States Study Group. Multicenter controlled trial comparing ceftibuten with amoxicillin/clavulanate in the empiric treatment of acute otitis media. Pediatr Infect Dis 1993; 12: S70-6.
21. Zeckel ML. Loracarbef (LY 163892) in the treatment of acute exacerbations of chronic bronchitis. Results of US and European comparative clinical trials. Am J Med 1992; 92(suppl 6A): 58S-64S.
22. Mendelman PM, Del Beccaro M, McLinn SE, Todd WM. Cefpodoxime proxetil compared with amoxicillin-clavulanate for the treatment of otitis media. J Pediatr 1992; 121: 460-5.
23. Periti P, Novelli A, Schildwachter G, Schmidt-Gayk H, Ryo Y, Zuck P. Efficacy and tolerance of cefpodoxime proxetil compared with co-amoxiclav in the treatment of exacerbations of chronic bronchitis. J Antimicrob Chemother 1990; 26(suppl E): 63-9.
24. Neu H, Wilson APR, Grüneberg RN. Amoxycillin/clavulanic acid: a review of its efficacy in over 38500 patients from 1979 to 1992. J Chemother 1993; 5: 67-93.
25. Mittermayer HW. The effect of amoxicillin plus clavulanic acid on human bowel flora. In: Proceedings of the European Symposium on Augmentin, Scheweningen, 1982; 125-33.
26. Motohiro T, Tanaka K, Koga T, et al. Clinical trials of BRL25000 (clavulanic acid-amoxicillin) on bacterial flora in human feces. Jpn Antibiot 1985; 38: 507-37.
27. Borderon JC, Rastegar A, Rolland JC, Laugier J. Effet de l'association amoxicilline-acide clavulanique sur la flore fecale aérobie de l'enfant. Pathol Biol 1985; 33: 569-72.
28. Brumfitt W, Franklin I, Grady D, Hamilton-Miller JMT. Effect of amoxicillin-clavulanate and cephradine in the fecal flora on healthy volunteers not exposed to a hospital environment. Antimicrob Agents Chemother 1986; 30: 335-7.
29. Heimdahl A, Nord CE. Effect of phenoxymethylpenicillin and clindamycm on the oral, throat and faecal microflora of man. Scand J Infect Dis 1979; 11: 233-42.
30. Aronsson B, Mollby R, Nord CE. Occurrence of toxin-producing Clostridium difficile in antibiotic-associated diarrhea. Med Microbiol Immunol 1981; 170: 27-35.
31. Olsson B, Nord CE, Wadström T. Formation of beta-lactamase in Bacteroides fragilis: cell-bound and extracellular activity. Antimicrob Agents Chemother 1976; 9: 727-35.
32. Stark C, Adamsson C, Edlund S. et al. Effects of omeprazole and amoxycillin on the human oral and gastrointestinal microflora in patients with Helicobacter pylori infections. J Antimicrob Chemother 1996; 38: 927-39.
33. Reeves DS, Bywater MJ. Assay of antimicrobial agents. In de Louvois J, ed. Selected topics in clinical bacteriology. London: Balliere Tyndall, 1976: 21-78.
34. Jones B, Kenward MG. Design and analysis of cross-over trials. New York: Chapman and Hall, 1989.
35. Senn S. Cross-over trials in clinical research. New York: John Wiley & Sons, 1993.
36. Gibaldi M. Biopharmaceutics and clinical pharmacokinetics, 4th edn. Philadelphia, London: Lea & Febiger, 1991.
37. Sachs L. Multiple Vergleiche verbundener Stichproben nach Wilcoxon and Wilcox. In: Angewandte Statistik. Anwendung statistischer Methoden, 8th edn. Berlin, Heidelberg, New York: Springer-Verlag, 1991: 673-5.
38. Spector S. Review of the properties and features of ceftibuten: a new orally active antibiotic. Infect Dis Clin Pract 1995; 4: S113-23.
39. Barr WM, Lin CC, Radwanski E, Lim J, Symchwicz S, Affrime M. The pharmacokinetics of ceftibuten in humans. Diagn Microbiol Infect Dis 1991; 14: 93-100.
40. Wise R, Nye K, O'Neill P, Wostenholme M, Andrews JM. Pharmacokinetics and tissue penetration of ceftibuten. Antimicrob Agents Chemother 1990; 34: 1053-5.
41. Kearns GL, Young RA. Ceftibuten pharmacokinetics and pharmacodynamics. Focus on paediatric use. Clin Pharmacokinet 1994; 26: 169-89.
42. Chocas EC, Paap CM, Godley PJ. Cefpodoxime proxetil: a new, broad-spectrum, oral cephalosporin. Ann Pharmacother 1993; 27: 1369-77.
43. Borin MT, Hughes GS, Patel RK, Royer ME, Cathcart KS. Pharmacokinetic and tolerance studies of cefpodoxime after single-and multiple-dose oral administration of cefpodoxime proxetil. J Clin Pharmacol 1991; 31: 1137-45.
44. Borin MT, Ferry JJ, Forbes KK, Hughes GS. Pharmacokinetics of cefpodoxime proxetil in healthy young and elderly volunteers. J Clin Pharmacol 1994; 34: 774-81.
45. Johnson CA, Ateshkadi A, Zimmerman SW, et al. Pharmacokinetics and ex vivo susceptibility of cefpodoxime proxetil in patients receiving continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 1993; 37: 2650-5.
46. Saathoff N, Lode H, Neider K, Deppermann KM, Borner K, Koeppe P. Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. Antimicrob Agents Chemother 1992; 36: 796-800.
47. Tremblay D, Dupront A, Ho C, Cossediere D, Lenfant B. Pharmacokinetics of cefpodoxime in young and elderly volunteers after singe doses. J Antimicrob Chemother 1990; 26(suppl E): 21-8.
48. Hughes GS, Heald DL, Barker KL, et al. The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil. Clin Pharmacol Ther 1989; 46: 674-85.
49. Deppermann KM, Garbe C, Hasse K, Borner K, Koeppe P, Lode H. Comparative pharmacokinetics of cefotixam hexetil, cefuroxime, cefixime, cephalexin and effect of H2 blockers, standard breakfast and antacids on the bioavailability of cefuroxime hexetil [abstract]. In: 29th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1989: 309.
50. Adam D, De Visser I, Koeppe R. Pharmacokinetics of amoxicillin and clavulanic acid administered alone and in combination. Antimicrob Agents Chemother 1982; 22: 353-7.
51. Jackson D, Cooper DL, Fier CW, Langley PP. Augmentin: absorption, excretion and pharmacokinetic studies in man. Postgrad Med 1984; 76(suppl): 51-70.
52. Fraschini F, Scaglione F, Falchi M, et al. Pharmacokinetics and tissue distribution of amoxicillin plus clavulanic acid after oral administration in man. J Chemother 1990; 2: 171-7.
53. Wise R, Bennett SA, Dent J. The pharmacokinetics of orally absorbed cefuroxime compared with amoxicillin/clavulanic acid. J Antimicrob Chemother 1984; 13: 603-10.
54. Nilsson-Ehle I, Fellner H, Hedström SA, Nilsson-Ehle P. Sjövall J. Pharmacokinetics of clavulanic acid, given in combination with amoxicillin, in volunteers. J Antimicrob Chemother 1985; 16: 491-8.
55. English AR, Retsema HA, Girard AE, Lynch JE, Barth WE. CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization. Antimicrob Agents Chemother 1978; 14: 414-19.
56. Münch R, Lüthy R, Blaser J, Siegenthaler W. Human pharmacokinetics and CSF penetration of clavulanic acid. J Antimicrob Chemother 1981; 8: 29-37.
57. Gould IM, Reid TMS, Legge JS. Amoxicillin/clavulanic acid levels in lower respiratory secretions. J Antimicrob Chemother 1988; 22: 88-90.
58. van der Waaij D. Colonization pattern of the digestive tract by potentially pathogenic microorganisms and consequences for antibiotic treatment. Infection 1983; 11: 90-2.
59. Nord CE, Edlund C. Impact of antimicrobial agents on human intestinal microflora. J Chemother 1990; 2: 218-37.
60. Edlund C. Stark C. Nord CE. The relationship between an increase in β-lactamase activity after oral administration of three new cephalosporins and protection against intestinal ecological disturbances. J Antimicrob Chemother 1994; 34: 127-38.
61. Krueger WA, Ruckdeschel G, Unertl K. Influence of intravenously administered ciprofloxacin on aerobic intestinal microflora and fecal drug levels when administered simultaneously with sucralfate. Antimicrob Agents Chemother 1997; 41: 1725-30.
62. De Vries-Hospers H, Jansen G, Tonk R, Oenema D, van der Waaij D. The in vitro inactivation of thirteen β-lactam antibiotics by other mechanisms than adsorption to faecal substance. Infection 1993; 21: 127-30.
63. Borin MT. A review of the pharmacokinetics of cefpodoxime proxetil. Drugs 1991; 42(suppl 3): 13-21.
64. Todd PH, Benfield P. Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1990; 39: 264-307.
65. Chachaty E, Depitre C, Mario N, et al. Presence of Clostridium difficile and antibiotic and beta-lactamase activities in feces of volunteers treated with oral cefixime, oral cefpodoxime proxetil, or placebo. Antimicrob Agents Chemother 1992; 36: 2009-13.
66. Kelly CP, Pothoulakis C. LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330: 257-62.
67. Samore HM, DeGirolami PC, Tlucko A, Lichtenberg DA, Melvin ZA, Karchmer AW. Clostridium difficile colonization and diarrhea at a tertiary care hospital. Clin Infect Dis 1994; 18: 181-7.
68. Croydon P. A worldwide survey of clinical experience with augmentin. J Drug Dev 1989; 2(suppl 1): 67-9.
69. De Abate CA, Perrotta RJ, Dennington ML, Ziering RM. The efficacy and safety of once-daily ceftibuten compared with co-amoxiclav in the treatment of acute bacterial sinusitis. J Chemother 1992; 4: 358-63.